M Kyla Shea1, Kathryn Barger1, Sarah L Booth1, Gregory Matuszek1, Mary Cushman2, Emelia J Benjamin3, Stephen B Kritchevsky4, Daniel E Weiner5. 1. Tufts University USDA Human Nutrition Research Center on Aging, Boston, MA, USA. 2. Larner College of Medicine, University of Vermont, Burlington, VT, USA. 3. Boston University School of Medicine and Public Health, Boston, MA, USA. 4. Sticht Center for Healthy Aging and Alzheimer's Prevention, Wake Forest School of Medicine, Winston-Salem, NC, USA. 5. Tufts Medical Center, Division of Nephrology, Boston, MA, USA.
Abstract
BACKGROUND: Vitamin K-dependent proteins in vascular tissue affect vascular stiffness and calcification, which is associated with cardiovascular disease (CVD) and all-cause mortality. OBJECTIVE: To determine the association of circulating vitamin K concentrations with CVD and all-cause mortality by conducting a participant-level meta-analysis. METHODS: We obtained individual participant-level data from the Health, Aging, and Body Composition Study, the Multi-Ethnic Study of Atherosclerosis, and the Framingham Offspring Study, known cohorts with available measures of fasting circulating phylloquinone (vitamin K-1) and confirmed CVD events and mortality. Circulating phylloquinone was measured in a central laboratory from fasting blood samples and categorized as ≤0.5 nmol/L, >0.5-1.0 nmol/L, and >1.0 nmol/L. Multivariable Cox proportional hazard regression with multiple imputations was used to evaluate the association of circulating phylloquinone with incident CVD and all-cause mortality risk. RESULTS: Among 3891 participants (mean age 65 ± 11 y; 55% women; 35% nonwhite), there were 858 incident CVD events and 1209 deaths over a median of 13.0 y. The risk of CVD did not significantly differ according to circulating phylloquinone [fully adjusted HR (95% CI) relative to >1.0 nmol/L: ≤0.5 nmol/L, 1.12 (0.94, 1.33); >0.5-1.0 nmol/L, 1.02 (0.86, 1.20)]. Participants with ≤0.5 nmol/L circulating phylloquinone had an adjusted 19% higher risk of all-cause mortality compared with those with >1.0 nmol/L [fully adjusted HR (95% CI): 1.19 (1.03, 1.38)]. Mortality risk was similar in participants with >0.5-1.0 nmol/L compared with >1.0 nmol/L [fully adjusted HR (95% CI): 1.04 (0.92, 1.17)]. CONCLUSIONS: Low circulating phylloquinone concentrations were associated with an increased risk of all-cause mortality, but not of CVD. Additional studies are needed to clarify the mechanism underlying this association and evaluate the impact of increased phylloquinone intake on cardiovascular and other health outcomes in individuals with low vitamin K status.
BACKGROUND:Vitamin K-dependent proteins in vascular tissue affect vascular stiffness and calcification, which is associated with cardiovascular disease (CVD) and all-cause mortality. OBJECTIVE: To determine the association of circulating vitamin K concentrations with CVD and all-cause mortality by conducting a participant-level meta-analysis. METHODS: We obtained individual participant-level data from the Health, Aging, and Body Composition Study, the Multi-Ethnic Study of Atherosclerosis, and the Framingham Offspring Study, known cohorts with available measures of fasting circulating phylloquinone (vitamin K-1) and confirmed CVD events and mortality. Circulating phylloquinone was measured in a central laboratory from fasting blood samples and categorized as ≤0.5 nmol/L, >0.5-1.0 nmol/L, and >1.0 nmol/L. Multivariable Cox proportional hazard regression with multiple imputations was used to evaluate the association of circulating phylloquinone with incident CVD and all-cause mortality risk. RESULTS: Among 3891 participants (mean age 65 ± 11 y; 55% women; 35% nonwhite), there were 858 incident CVD events and 1209 deaths over a median of 13.0 y. The risk of CVD did not significantly differ according to circulating phylloquinone [fully adjusted HR (95% CI) relative to >1.0 nmol/L: ≤0.5 nmol/L, 1.12 (0.94, 1.33); >0.5-1.0 nmol/L, 1.02 (0.86, 1.20)]. Participants with ≤0.5 nmol/L circulating phylloquinone had an adjusted 19% higher risk of all-cause mortality compared with those with >1.0 nmol/L [fully adjusted HR (95% CI): 1.19 (1.03, 1.38)]. Mortality risk was similar in participants with >0.5-1.0 nmol/L compared with >1.0 nmol/L [fully adjusted HR (95% CI): 1.04 (0.92, 1.17)]. CONCLUSIONS: Low circulating phylloquinone concentrations were associated with an increased risk of all-cause mortality, but not of CVD. Additional studies are needed to clarify the mechanism underlying this association and evaluate the impact of increased phylloquinone intake on cardiovascular and other health outcomes in individuals with low vitamin K status.
Authors: D K Houston; J Ding; J S Lee; M Garcia; A M Kanaya; F A Tylavsky; A B Newman; M Visser; S B Kritchevsky Journal: Nutr Metab Cardiovasc Dis Date: 2010-03-24 Impact factor: 4.222
Authors: Diane E Bild; Robert Detrano; Do Peterson; Alan Guerci; Kiang Liu; Eyal Shahar; Pamela Ouyang; Sharon Jackson; Mohammed F Saad Journal: Circulation Date: 2005-03-15 Impact factor: 29.690
Authors: Sabine R Zwakenberg; Nicole R den Braver; Anouk I P Engelen; Edith J M Feskens; Cees Vermeer; Jolanda M A Boer; W M Monique Verschuren; Yvonne T van der Schouw; Joline W J Beulens Journal: Clin Nutr Date: 2016-08-30 Impact factor: 7.324
Authors: Nicola M McKeown; Paul F Jacques; Caren M Gundberg; James W Peterson; Katherine L Tucker; Douglas P Kiel; Peter W F Wilson; Sarah L Booth Journal: J Nutr Date: 2002-06 Impact factor: 4.798
Authors: Daniel Bos; Maarten J G Leening; Maryam Kavousi; Albert Hofman; Oscar H Franco; Aad van der Lugt; Meike W Vernooij; M Arfan Ikram Journal: Circ Cardiovasc Imaging Date: 2015-12 Impact factor: 7.792
Authors: Ralph B D'Agostino; Ramachandran S Vasan; Michael J Pencina; Philip A Wolf; Mark Cobain; Joseph M Massaro; William B Kannel Journal: Circulation Date: 2008-01-22 Impact factor: 29.690
Authors: Sameera A Talegawkar; Elizabeth J Johnson; Teresa C Carithers; Herman A Taylor; Margaret L Bogle; Katherine L Tucker Journal: J Am Diet Assoc Date: 2008-12
Authors: M Kyla Shea; Kathryn Barger; Sarah L Booth; Jifan Wang; Harold I Feldman; Raymond R Townsend; Jing Chen; John Flack; Jiang He; Bernard G Jaar; Mayank Kansal; Sylvia E Rosas; Daniel E Weiner Journal: Am J Clin Nutr Date: 2022-03-04 Impact factor: 8.472
Authors: Claire R Palmer; Jamie W Bellinge; Frederik Dalgaard; Marc Sim; Kevin Murray; Emma Connolly; Lauren C Blekkenhorst; Catherine P Bondonno; Kevin D Croft; Gunnar Gislason; Anne Tjønneland; Kim Overvad; Carl Schultz; Joshua R Lewis; Jonathan M Hodgson; Nicola P Bondonno Journal: Eur J Epidemiol Date: 2021-09-30 Impact factor: 8.082
Authors: M Kyla Shea; Kathleen L Berkner; Guylaine Ferland; Xueyan Fu; Rachel M Holden; Sarah L Booth Journal: Adv Nutr Date: 2021-06-01 Impact factor: 8.701